Cagrilintide + Tirzepatide
Triple-pathway satiety stack combining amylin agonism with dual GLP-1/GIP incretin signaling for maximum appetite suppression.
Fat loss Beginner 24 weeks titration + open-ended maintenance
24-hour timeline
0:00 6:00 12:00 18:00 24:00
- Cagrilintide
- Tirzepatide
Protocol
Both compounds once weekly SubQ, same day at different injection sites. Staggered 24-week titration. Tirzepatide alone for the first 8 weeks: 2.5 mg (weeks 1-4), 5.0 mg (weeks 5-8). At week 9 introduce cagrilintide: tirzepatide 5.0 mg + cagrilintide 0.25 mg (weeks 9-12), tirzepatide 7.5 mg + cagrilintide 0.5 mg (weeks 13-16), tirzepatide 10 mg + cagrilintide 1.0 mg (weeks 17-20), tirzepatide 12.5 mg + cagrilintide 1.7 mg (weeks 21-24). Maintenance from week 25+: tirzepatide 15 mg + cagrilintide 2.4 mg weekly.